These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16633863)

  • 1. Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis.
    Lynde C
    J Cutan Med Surg; 2006; 9 Suppl 1():1-3. PubMed ID: 16633863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence.
    Poulin Y; Papp KA; Carey W; Gulliver W; Gupta AK
    J Cutan Med Surg; 2006; 9 Suppl 1():10-7. PubMed ID: 16633861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
    Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
    J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efalizumab for the treatment of moderate to severe plaque psoriasis.
    Jordan JK
    Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis".
    Ginarte M
    J Am Acad Dermatol; 2011 Jun; 64(6):1184; author reply 1184-5. PubMed ID: 21571182
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
    Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
    Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
    Schön MP
    Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
    Lowes MA; Turton JA; Krueger JG; Barnetson RS
    BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
    Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
    Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice].
    Dirschka T; Reinhold U; Rosenbach T; Schubert E; Sebastian M; Streit V
    J Dtsch Dermatol Ges; 2006 Oct; 4 Suppl 1():S3-S12. PubMed ID: 17022742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.